Latest Breaking News On - Shelley force aldred - Page 1 : vimarsana.com

Rondo Therapeutics to Showcase Next-Generation CD28 Bispecific Platform at Upcoming Therapeutic Antibody Conferences

Rondo Therapeutics to Showcase Next-Generation CD28 Bispecific Platform at Upcoming Therapeutic Antibody Conferences
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomCity ofStarlynn clarkeMeghana raoNathand trinkleinBusiness developmentProtein antibody engineering society bostonShelley force aldredRondo therapeuticsProtein antibody engineering summitAntibody engineering therapeuticsAntibody engineering societyBispecific antibody combination strategiesTreating solid tumorsCo stimulatory bispecific antibody strategies

Startup Ancora Biotech snags $60M following founders big Amgen buyout last year

Startup Ancora Biotech snags $60M following founders big Amgen buyout last year
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.

Roland buelowBen buelowNathan trinkleinemergedAmgen incTeneobio incShelley force aldredAncora biotechLightspeed venture partnersRondo therapeutics

SwitchGear Genomics | SelectScience

SwitchGear Genomics products, product reviews and application articles on SelectScience.

Richard myersNathan trinkleinShelley force aldredStanford universityGear genomicsSwitchgear genomics

Cancer biotech Rondo gets $67M to step on the gas with next-gen bispecific drugs

Rondo Therapeutics is developing bispecific antibody drugs capable of treating solid tumors, which have eluded this type of cancer therapy. Led by co-founders and Teneobio veterans Shelley Force Aldred and Nathan Trinklein, the biotech startup has emerged from stealth backed by a $67 million Series A round of funding.

United statesNathan trinkleinAmunix pharmaceuticalsSv health investorsBristol myers squibbShelley force aldredNovo holdingsRondo therapeuticsForce aldredSan francisco basedMaverick therapeuticsRed tree venture capitalJohnson innovationWeight lossMedical devicesHealthcare innovation

Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors

/PRNewswire/ Rondo Therapeutics, a biopharmaceutical company advancing a next-generation immuno-oncology platform for treating solid tumors, today announced.

Jon edwardsNils lonbergNina kjellsonNathan trinkleinSv health investorsShelley force aldredJjdc incNovo holdingsRondo therapeuticsRed tree venture capitalCanaan partnersJohnson innovationRed treeForce aldredStrategic partners